Manipulation of the host protein acetylation network by human immunodeficiency virus type 1

Critical Reviews in Biochemistry and Molecular Biology

Volumn 50, Issue 4, 2015, Pages 314-325

  Jeng, Mark Y ^a,b   Ali, Ibraheem ^a,b   Ott, Melanie ^a,b  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epigenetic regulation; latency; post translational modification; therapeutic inhibitors; viral infection; virus host interactions

Indexed keywords

BROMODOMAIN INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ENZYME INHIBITOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; ISOENZYME;

CD4+ T LYMPHOCYTE; GENE SILENCING; HOST; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; REVIEW; VIRUS CELL INTERACTION; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY; VIRUS TRANSCRIPTION; ACETYLATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECTS; HIV INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PROTEIN PROCESSING; VIROLOGY;

ACETYLATION; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; ENZYME INHIBITORS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; ISOENZYMES; MODELS, IMMUNOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84942295089     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2015.1061973     Document Type: Review

References (157)

1. Akella JS, Wloga D, Kim J, et al. (2010). MEC-17 is an alpha-tubulin acetyltransferase. Nature 467:218-22.
2. Ali M, Yan K, Lalonde M-E, et al. (2012). Tandem PHD fingers of MORF/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin. J Mol Biol 424:328-38.
3. Allouch A, Cereseto A. (2009). Identification of cellular factors binding to acetylated HIV-1 integrase. Amino Acids 41:1137-45.
4. Allouch A, Di Primio C, Alpi E, et al. (2011). The TRIM family protein KAP1 inhibits HIV-1 integration. Cell Host Microbe 9:484-95.
5. Archin NM, Bateson R, Tripathy MK, et al. (2014). HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis 210:728-35.
6. Archin NM, Cheema M, Parker D, et al. (2010). Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 5:e9390.
7. Archin NM, Espeseth A, Parker D, et al. (2009). Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25:207-12.
8. Baeza J, Dowell JA, Smallegan MJ, et al. (2014). Stoichiometry of sitespecific lysine acetylation in an entire proteome. J Biol Chem 289: 21326-38.
9. Bagley JA, Yan Z, Zhang W, et al. (2014). Double-bromo and extraterminal (BET) domain proteins regulate dendrite morphology and mechanosensory function. Genes Dev 28:1940-56.
10. Balasubramanyam K, Altaf M, Varier RA, et al. (2004a). Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 279:33716-26.
11. Balasubramanyam K, Varier RA, Altaf M, et al. (2004b). Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279:51163-71.
12. Banerjee C, Archin N, Michaels D, et al. (2012). BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 92:1147-54.
13. Bartholomeeusen K, Xiang Y, Fujinaga K, et al. (2012). Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 287:36609-16.
14. Barton KM, Archin NM, Keedy KS, et al. (2014). Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One 9:e102684.
15. Benkirane M, Chun RF, Xiao H, et al. (1998). Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem 273:24898-905.
16. Berndsen CE, Denu JM. (2008). Catalysis and substrate selection by histone/protein lysine acetyltransferases. Curr Opin Struct Biol 18: 682-9.
17. Bertino EM, Otterson GA. (2011). Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 20: 1151-8.
18. Bisgrove DA, Mahmoudi T, Henklein P, et al. (2007). Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci USA 104:13690-5.
19. Black JC, Choi JE, Lombardo SR, et al. (2006). A mechanism for coordinating chromatin modification and preinitiation complex assembly. Mol Cell 23:809-18.
20. Black JC, Mosley A, Kitada T, et al. (2008). The SIRT2 deacetylase regulates autoacetylation of p300. Mol Cell 32:449-55.
21. Blazkova J, Chun TW, Belay BW, et al. (2012). Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4+ T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 206:765-9.
22. Boehm D, Calvanese V, Dar RD, et al. (2013a). BET bromodomaintargeting compounds reactivate HIV from latency via a Tatindependent mechanism. Cell Cycle 12:452-62.
23. Boehm D, Conrad R, Ott M. (2013b). Bromodomain proteins in HIV infection. Viruses 5:1571-86.
24. Bradner JE, West N, Grachan ML, et al. (2010). Chemical phylogenetics of histone deacetylases. Nat Meth 6:238-43.
25. Bullen CK, Laird GM, Durand CM, et al. (2014). New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20:425-9.
26. Campbell GR, Bruckman RS, Chu Y-L, et al. (2014). Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. J Biol Chem 290:5028-40.
27. Caron CC, Col E, Khochbin S. (2002). The viral control of cellular acetylation signaling. Bioessays 25:58-65.
28. Cereseto A, Manganaro L, Gutierrez MI, et al. (2005). Acetylation of HIV-1 integrase by p300 regulates viral integration. EMBO J 24: 3070-81.
29. Cheng F, Lienlaf M, Wang HW, et al. (2014). A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol 193:2850-62.
30. Cho S, Schroeder S, Kaehlcke K, et al. (2009). Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cells. EMBO J 28:1407-17.
31. Cho S, Schroeder S, Ott M. (2010). CYCLINg through transcription: posttranslational modifications of P-TEFb regulate transcription elongation. Cell Cycle 9:1697-705.
32. Chomont N, El-Far M, Ancuta P, et al. (2009). HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900.
33. Choudhary C, Kumar C, Gnad F, et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834-40.
34. Chun TW, Stuyver L, Mizell SB, et al. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94:13193-7.
35. Cillo AR, Sobolewski MD, Bosch RJ, et al. (2014). Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 111: 7078-83.
36. Col E, Caron C, Seigneurin-Berny D, et al. (2001). The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J Biol Chem 276:28179-84.
37. Core LJ, Waterfall JJ, Lis JT. (2008). Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322:1845-48.
38. Del Prete GQ, Shoemaker R, Oswald K, et al. (2014). Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapymediated suppression in SIVmac239-infected Indian rhesus macaques. Antimicrob Agents Chemother 58:6790-806.
39. Deng L, de la Fuente C, Fu P, et al. (2000). Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277:278-95.
40. Deng W-G, Zhu Y, Wu KK. (2003). Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase- 2 promoter activation. J Biol Chem 278:4770-7.
41. Dorr A, Kiermer V, Pedal A, et al. (2002). Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J 21:2715-23.
42. D'Orso I, Frankel AD. (2009). Tat acetylation modulates assembly of a viral-host RNA-protein transcription complex. Proc Natl Acad Sci USA 106:3101-6.
43. Elliott J, Solomon A, Wightman F, et al. (2013). The safety and effect of multiple doses of vorinostat on HIV transcription in HIV+ patients receiving cART. 20th Conference on Retroviruses and Opportunistic Infections.
44. Fahey ME, Bennett MJ, Mahon C, et al. (2011). GPS-Prot: a web-based visualization platform for integrating host-pathogen interaction data. BMC Bioinformatics 12:298.
45. Falkenberg KJ, Johnstone RW. (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13:673-91.
46. Fassati A. (2012). Multiple roles of the capsid protein in the early steps of HIV-1 infection. Virus Res 170:15-24.
47. Filippakopoulos P, Knapp S. (2014). Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13:337-56.
48. Filippakopoulos P, Picaud S, Mangos M, et al. (2012). Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149:214-31.
49. Filippakopoulos P, Qi J, Picaud S, et al. (2010). Selective inhibition of BET bromodomains. Nature 468:1067-73.
50. Fischer M, Joos B, Hirschel B, et al. (2004). Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. J Infect Dis 190:1979-88.
51. Franke EK, Yuan HE, Luban J. (1994). Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359-62.
52. French CA. (2012). Pathogenesis of NUT midline carcinoma. Annu Rev Pathol Mech Dis 7:247-65.
53. Fu J, Yoon HG, Qin J, et al. (2007). Regulation of P-TEFb elongation complex activity by CDK9 acetylation. Mol Cell Biol 27:4641-51.
54. Furia B, Deng L, Wu K, et al. (2002). Enhancement of nuclear factorkappa B acetylation by coactivator p300 and HIV-1 Tat proteins. J Biol Chem 277:4973-80.
55. Furlan A, Monzani V, Reznikov LL, et al. (2011). Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 17: 353-62.
56. Gautier VW, Gu L, O'Donoghue N, et al. (2009). In vitro nuclear interactome of the HIV-1 Tat protein. Retrovirology 6:47.
57. Hakre S, Chavez L, Shirakawa K, et al. (2011). Epigenetic regulation of HIV latency. Curr Opin HIV AIDS 6:19-24.
58. Halili MA, Andrews MR, Labzin LI, et al. (2010). Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 87:1103-14.
59. Halper-Stromberg A, Lu C-L, Klein F, et al. (2014). Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158:989-99.
60. Han Y, Jeong HM, Jin Y-H, et al. (2009). Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity. Biochem Biophys Res Commun 383:88-92.
61. Han Y, Jin Y-H, Kim Y-J, et al. (2008). Acetylation of Sirt2 by p300 attenuates its deacetylase activity. Biochem Biophys Res Commun 375:576-80.
62. Harrod R, Nacsa J, Van Lint C, et al. (2003). Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J Biol Chem 278:12310-18.
63. He N, Liu M, Hsu J, et al. (2010). HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol Cell 38:428-38.
64. Hottiger MO, Nabel GJ. (1998). Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J Virol 72:8252-6.
65. Houtkooper RH, Pirinen E, Auwerx J. (2012). Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13:225-38.
66. Huo L, Li D, Sun X, et al. (2011). Regulation of Tat acetylation and transactivation activity by the microtubule-associated deacetylase HDAC6. J Biol Chem 286:9280-6.
67. Jäger S, Cimermancic P, Gulbahce N, et al. (2012). Global landscape of HIV-human protein complexes. Nature 481:365-70.
68. Jensen ON. (2006). Interpreting the protein language using proteomics. Nat Rev Mol Cell Biol 7:391-403.
69. Jiang G, Mendes EA, Kaiser P, et al. (2014). Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS 28:1555-66.
70. Jolly C, Mitar I, Sattentau QJ. (2007). Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1. J Virol 81:5547-60.
71. Jones P, Altamura S, De Francesco R, et al. (2008). Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett 18:1814-19.
72. Jones RB, O'Connor R, Mueller S, et al. (2014). Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog 10:e1004287.
73. Josling GA, Selvarajah SA, Petter M, et al. (2012). The role of bromodomain proteins in regulating gene expression. Genes 3:320-43.
74. Kaehlcke K, Dorr A, Hetzer-Egger C, et al. (2003). Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol Cell 12:167-76.
75. Kamine J, Elangovan B, Subramanian T, et al. (1996). Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 216:357-66.
76. Kao SY, Calman AF, Luciw PA, et al. (1987). Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330:489-93.
77. Kaufmann DE, Lichterfeld M, Altfeld M, et al. (2004). Limited durability of viral control following treated acute HIV infection. PLoS Med 1:e36.
78. Kiernan RE, Vanhulle C, Schiltz L, et al. (1999). HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J 18:6106-18.
79. Kino T, Gragerov A, Slobodskaya O, et al. (2002). Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 76:9724-34.
80. Klase Z, Yedavalli VSRK, Houzet L, et al. (2014). Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA. PLoS Pathog 10:e1003997.
81. Kwon H-S, Brent MM, Getachew R, et al. (2008). Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3:158-67.
82. Lammers M, Neumann H, Chin JW, et al. (2010). Acetylation regulates cyclophilin A catalysis, immunosuppression and HIV isomerization. Nat Chem Biol 6:331-7.
83. Lewin SR, Murray JM, Solomon A, et al. (2008). Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. J Acquir Immune Defic Syndr 47:140-7.
84. Li T, Du Y, Wang L, et al. (2012a). Characterization and prediction of lysine (K)-acetyl-transferase specific acetylation sites. Mol Cell Proteomics 11:M111.011080.
85. Li Z, Guo J, Wu Y, et al. (2012b). The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 41:277-87.
86. Li Y, Wen H, Xi Y, et al. (2014). AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 159: 558-71.
87. Lin P-H, Ke Y-Y, Su C-T, et al. (2011). Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway. J Virol 85:9114-26.
88. Loetscher P, Moser B, Baggiolini M. (2000). Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol 74: 127-80.
89. Loosveld M, Castellano R, Gon S, et al. (2014). Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. Oncotarget 5:3168-72.
90. Lucera MB, Tilton CA, Mao H, et al. (2014). The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. J Virol 88:10803-12.
91. Mahmoudi T, Parra M, Vries RGJ, et al. (2006). The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem 281:19960-8.
92. Matalon S, Palmer BE, Nold MF, et al. (2010). The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 54: 1-9.
93. Mantelingu K, Reddy BAA, Swaminathan V, et al. (2007). Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem Biol 14:645-57.
94. Marzio G, Tyagi M, Gutierrez MI, et al. (1998). HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci USA 95:13519-24.
95. Matzuk MM, McKeown MR, Filippakopoulos P, et al. (2012). Smallmolecule inhibition of BRDT for male contraception. Cell 150: 673-84.
96. McDonald D, Vodicka MA, Lucero G, et al. (2002). Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 159: 441-52.
97. Mujtaba S, He Y, Zeng L, et al. (2002). Structural basis of lysineacetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell 9: 575-86.
98. Naranatt PP, Krishnan HH, Smith MS, et al. (2004). Kaposi's sarcomaassociated herpesvirus modulates microtubule dynamics via RhoAGTP-diaphanous 2 signaling and utilizes the dynein motors to deliver its DNA to the nucleus. J Virol 79:1191-206.
99. Neumann H, Peak-Chew SY, Chin JW. (2008). Genetically encoding N∈-acetyllysine in recombinant proteins. Nat Chem Biol 4:232-34.
100. Nicodeme E, Jeffrey KL, Schaefer U, et al. (2010). Suppression of inflammation by a synthetic histone mimic. Nature 468:1119-23.
101. North BJ, Marshall BL, Borra MT, et al. (2003). The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11:437-44.
102. Ott M, Geyer M, Zhou Q. (2011). The control of HIV transcription: Keeping RNA polymerase II on track. Cell Host Microbe 10:426-35.
103. Ott M, Schnolzer M, Garnica J, et al. (1999). Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol 9:1489-92.
104. Pagans S, Pedal A, North BJ, et al. (2005). SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 3:e41.
105. Pan C, Mezei M, Mujtaba S, et al. (2007). Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding proteinassociated factor. J Med Chem 50:2285-8.
106. Perdiz D, Mackeh R, Poüs C, et al. (2011). The ins and outs of tubulin acetylation: more than just a post-translational modification? Cell Signal 23:763-71.
107. Piperno G, LeDizet M, Chang XJ. (1987). Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. J Cell Biol 104:289-302.
108. Qiu Y, Liu L, Zhao C, et al. (2012). Combinatorial readout of unmodified H3R2 and acetylated H3K14 by the tandem PHD finger of MOZ reveals a regulatory mechanism for HOXA9 transcription. Genes Dev 26:1376-91.
109. Qiu Y, Zhao Y, Becker M, et al. (2006). HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol Cell 22:669-79.
110. Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, et al. (2013). Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 9:993-1001.
111. Rasmussen TA, Tolstrup M, Brinkmann CR, et al. (2014). Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1:e13-21.
112. Rothgiesser KM, Erener S, Waibel S, et al. (2010). SIRT2 regulates NF-kB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 123:4251-8.
113. Routy JP, Tremblay CL, Angel JB, et al. (2012). Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 13:291-6.
114. Ryu H, Lee J, Olofsson BA, et al. (2003). Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci USA 100:4281-6.
115. Sabò A, Lusic M, Cereseto A, et al. (2008). Acetylation of conserved lysines in the catalytic core of cyclin-dependent kinase 9 inhibits kinase activity and regulates transcription. Mol Cell Biol 28: 2201-12.
116. Sabo Y, Walsh D, Barry DS, et al. (2013). HIV-1 induces the formation of stable microtubules to enhance early infection. Cell Host Microbe 14:535-46.
117. Schröder S, Cho S, Zeng L, et al. (2012). Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J Biol Chem 287:1090-9.
118. Schröder S, Herker E, Itzen F, et al. (2013). Acetylation of RNA polymerase II regulates growth-factor-induced gene transcription in mammalian cells. Mol Cell 52:314-24.
119. Seal J, Lamotte Y, Donche F, et al. (2012). Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett 22: 2968-72.
120. Sgarbanti M, Battistini A. (2013). Therapeutics for HIV-1 reactivation from latency. Curr Opin Virol 3:394-401.
121. Shakespear MR, Halili MA, Irvine KM, et al. (2011). Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 32:335-43.
122. Shan L, Deng K, Shroff NS, et al. (2012). Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491-501.
123. Sheridan PL, Mayall TP, Verdin E, et al. (1997). Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev 11: 3327-40.
124. Shi J, Vakoc CR. (2014). The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell 54:728-36.
125. Shida T, Cueva JG, Xu Z, et al. (2010). The major alpha-tubulin K40 acetyltransferase alphaTAT1 promotes rapid ciliogenesis and efficient mechanosensation. Proc Natl Acad Sci USA 107:21517-22.
126. Shirakawa K, Chavez L, Hakre S, et al. (2013). Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 21:277-85.
127. Siliciano JD, Kajdas J, Finzi D, et al. (2003). Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727-8.
128. Sobhian B, Laguette N, Yatim A, et al. (2010). HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell 38:439-51.
129. Sorin M, Cano J, Das S, et al. (2009). Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication. PLoS Pathog 5:e1000463.
130. Spange S, Wagner T, Heinzel T, et al. (2009). Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41:185-98.
131. Su D, Hu Q, Li Q, et al. (2012). Structural basis for recognition of H3K56-acetylated histone H3-H4 by the chaperone Rtt106. Nature 482:104-7.
132. Terreni M, Valentini P, Liverani V, et al. (2010). GCN5-dependent acetylation of HIV-1 integrase enhances viral integration. Retrovirology 7:18.
133. Thali M, Bukovsky A, Kondo E, et al. (1994). Functional association of cyclophilin A with HIV-1 virions. Nature 372:363-5.
134. Thierry S, Marechal V, Rosenzwajg M, et al. (2004). Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter. J Virol 78:12198-206.
135. Topper M, Luo Y, Zhadina M, et al. (2007). Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxylterminal domain is dispensable for viral replication. J Virol 81: 3012-17.
136. Tschismarov R, Firner S, Gil-Cruz C, et al. (2014). HDAC1 controls CD8+ T cell homeostasis and antiviral response. PLoS One 9:e110576.
137. Valenzuela-Fernández A, Alvarez S, Gordon-Alonso M, et al. (2005). Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection. Mol Biol Cell 16:5445-54.
138. Van Lint C, Emiliani S, Ott M, et al. (1996). Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112-20.
139. Vendel AC, Lumb KJ. (2004). NMR mapping of the HIV-1 Tat interaction surface of the KIX domain of the human coactivator CBP. Biochemistry 43:904-8.
140. Verdin E, Ott M. (2014). 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol. 16:258-64.
141. Verdin E, Paras P, Van Lint C. (1993). Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12:3249-59.
142. Wang R, Li Q, Helfer CM, et al. (2012). Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J Biol Chem 287:10738-52.
143. Wei DG, Chiang V, Fyne E, et al. (2014). Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10:e1004071.
144. Weinberger LS, Burnett JC, Toettcher JE, et al. (2005). Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122:169-82.
145. Weinert BT, Iesmantavicius V, Moustafa T, et al. (2014). Acetylation dynamics and stoichiometry in Saccharomyces cerevisiae. Mol Syst Biol 10:716.
146. Weissman JD, Brown JA, Howcroft TK, et al. (1998). HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes. Proc Natl Acad Sci USA 95: 11601-6.
147. Wightman F, Ellenberg P, Churchill M, et al. (2012). HDAC inhibitors in HIV. Immunol Cell Biol 90:47-54.
148. Wong JK, Hezareh M, Günthard HF, et al. (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-5.
149. Wong K, Sharma A, Awasthi S, et al. (2005). HIV-1 Tat interactions with p300 and PCAF transcriptional coactivators inhibit histone acetylation and neurotrophin signaling through CREB. J Biol Chem 280:9390-9.
150. Yamamoto T, Horikoshi M. (1997). Novel substrate specificity of the histone acetyltransferase activity of HIV-1-Tat interactive protein Tip60. J Biol Chem 272:30595-8.
151. Yan B, Xie S, Liu Z, et al. (2014). HDAC6 deacetylase activity is critical for lipopolysaccharide-induced activation of macrophages. PLoS One 9:e110718.
152. Yeung F, Hoberg JE, Ramsey CS, et al. (2004). Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369-80.
153. Zeng L, Li J, Muller M, et al. (2005). Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J Am Chem Soc 127: 2376-7.
154. Zeng L, Zhang Q, Li S, et al. (2010). Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3b. Nature 466:258-62.
155. Zhang G, Liu R, Zhong Y, et al. (2012). Down-regulation of NF-kB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem 287:28840-51.
156. Zhang L, Ramratnam B, Tenner-Racz K, et al. (1999). Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340:1605-13.
157. Zhu J, Gaiha GD, John SP, et al. (2012). Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2:807-16.